Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Terminated Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0028534 (Adult Acute Minimally Differentiated Myeloid Leukemia (M0))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01465386Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in RemissionTreatment